Xarelto Tablet, Film Coated
Product Images NDC 55154-1424

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Xarelto (NDC 55154-1424). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ce538950 C1cf 4b9b 9434 A4b96c1d461e 00

This is a medicine package for a product made by Janssen Pharmaceuticals Inc. that includes an active ingredient made in Germany. The medicine is distributed by CardinalHealth and has an NDC number of 50458 579-50. The manufacturer is licensed by Bayer Healthcare AG. The rest of the text is not legible.*

FDA Label Image

Ce538950 C1cf 4b9b 9434 A4b96c1d461e 01

FDA Label Image

Ce538950 C1cf 4b9b 9434 A4b96c1d461e 02

XARELTO is a medication package containing 10 tablets of Rivaroxaban, each tablet having 10 mg of the active ingredient. This medication is used to prevent blood clots in various medical conditions. It is advised to store this package at room temperature, and it may not be child-resistant. This particular package is intended for hospital use only and is Rx only. A medication guide should be dispensed to each patient. It is manufactured in Germany and licensed from Bayer Healthcare AG, then marketed by Janssen Pharmaceuticals, Inc., and distributed by Cardinal Health. Refer to the product insert for complete prescribing information, precautions, and warnings.*

FDA Label Image

Figure 1 (Xarelto 01)

FDA Label Image

Chemical Structure (Xarelto 02)

FDA Label Image

Figure 2 (Xarelto 03)

FDA Label Image

Figure 3 (Xarelto 04)

This is a table that lists different types of interacting drugs with their PK (pharmacokinetic) fold change and 90% confidence interval. The drugs are categorized into combined P-gp and strong or moderate CYP3A inhibitors or inducers, as well as moderate CYP3A inhibitors. The names of the drugs listed are Clpeomyen, Epromyen, Fconazde, and "other drugs".*

FDA Label Image

Figure 4 (Xarelto 05)

XARELTO is a drug name, but the rest of the text seems to be numerical data and not a useful description.*

FDA Label Image

Figure 5 (Xarelto 06)

FDA Label Image

Figure 6 (Xarelto 07)

FDA Label Image

Figure 7 (Xarelto 08)

FDA Label Image

Figure 8 (Xarelto 09)

FDA Label Image

Xarelto 10

FDA Label Image

Xarelto 11

FDA Label Image

Xarelto 12

This appears to be a graph or chart displaying the cumulative incidence rate (%) over time (measured in days from randomization) for two groups - one treated with XARELTO and one treated with a placebo. It provides the number of events (either cases or individuals) in each group at different time points. However, without further context or information, the purpose or meaning of this data is not clear.*

FDA Label Image

Xarelto 13

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.